MACOP-B regimen followed by involved-field radiation therapy in early-stage aggresive non-Hodgkin's lymphoma patients: 14-year update results

Leukemia and Lymphoma

Volumn 42, Issue 5, 2001, Pages 989-995

  Zinzani, P L ^a   Stefoni, V ^a   Tani, M ^a   Barbieri, E ^a   Albertini, P ^a   Vigna, E ^a   Gherlinzoni, F ^a   Alinari, L ^a   Galuppi, A ^a   Pileri, S ^a   Babini, L ^a   Tura, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Aggressive NHL; Early stage; Long term follow up; MACOP B

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION FIELD; RETROSPECTIVE STUDY; SIDE EFFECT;

EID: 0034839520     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097718     Document Type: Article

References (20)

1. Long-term survival of patients with localized diffuse histiocytic lymphoma
2. The patterns of failure in patients with pathological stage I and II diffuse histiocytic lymphoma treated with radiation therapy alone
3. CVP-remission-maintenance in stage I or II non-Hodgkin's lymphomas: Preliminary results of a randomized study
4. Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types
5. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas
6. Initial chemotherapy for clinically localized lymphomas of unfavorable histology
7. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma
8. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotheraphy with or without adjuvant radiotherapy
9. Influence of therapy on local control and survival in stage I and II intermediate and high grade non-Hodgkin's lymphoma
10. Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage II aggressive histologic type non-Hodgkin's lymphoma
11. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas
12. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy
13. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma
14. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
15. Report of the Committee on Hodgkin's Disease Staging Classification
16. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma
17. Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients
18. Non-parametric estimation from incomplete observation
19. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
20. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma